Universal Vision Biotechnology Co (3218.TWO) Stock Price
Universal Vision Biotechnology Co Price
Over the last 19 years Universal Vision Biotechnology Co grew revenue by 14.2% annually, reaching 4.20 B TWD. Earnings per share have grown at 11.7% per year over the last 19 years. For Universal Vision Biotechnology Co, the net margin of 24.8% is up versus 22.6% a few years ago. At today's price the dividend yield works out to roughly 5.62%. The payout ratio is around 61% of earnings. The dividend has grown at 18.6% per year over the past 3 years. The consensus 12-month price target for Universal Vision Biotechnology Co is 172.38 TWD, about 29.1% above where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.
Universal Vision Biotechnology Co stock price
Universal Vision Biotechnology Co business model & stock analysis
Frequently asked questions about Universal Vision Biotechnology Co
Analysts currently set an average price target of 172.38 TWD for the Universal Vision Biotechnology Co stock (median: 172.38 TWD), implying +29.1 % versus the latest price. The consensus is based on 9 analyst ratings.
Universal Vision Biotechnology Co Analyst Price Targets 2026
9 analysts currently rate the Universal Vision Biotechnology Co stock: 0 recommend buying, 5 holding and 4 selling. For 2026, analysts expect Universal Vision Biotechnology Co to generate revenue of 4.58 B TWD and earnings per share of 13.12 TWD.
Universal Vision Biotechnology Co Analyst Price Targets 2026
Converted at the current exchange rate, the Universal Vision Biotechnology Co share trades at 3.73 EUR (133.50 TWD).
The expected revenue of Universal Vision Biotechnology Co is 4.58 B TWD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Universal Vision Biotechnology Co is 1.11 B TWD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Universal Vision Biotechnology Co is currently 10.18. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Universal Vision Biotechnology Co stock.
The price-to-sales ratio (P/S) of Universal Vision Biotechnology Co is currently 2.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Universal Vision Biotechnology Co stock.
The Eulerpool Quality Score for Universal Vision Biotechnology Co is 7/10.
The ISIN of Universal Vision Biotechnology Co is TW0003218004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Universal Vision Biotechnology Co is 3218.TWO. The ticker symbol is used to trade Universal Vision Biotechnology Co shares on the stock exchange.
Universal Vision Biotechnology Co stock
Universal Vision Biotechnology Co Peer Group
Universal Vision Biotechnology Co FIGI
All fundamentals and in-depth analysis of Universal Vision Biotechnology Co
Our stock analysis for Universal Vision Biotechnology Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Universal Vision Biotechnology Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.